CAMBRIDGE–Alnylam Pharmaceuticals announced Thursday that the U.S. Food and Drug Administration has approved Livsayis (cemdisiran), an RNA interference (RNAi) therapy discovered by Alnylam and developed by Regeneron Pharmaceuticals, for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
The approval makes Livsayis the seventh Alnylam-discovered RNAi therapeutic to receive FDA authorization in less than nine years and the first RNAi treatment approved for generalized myasthenia gravis.
Under its collaboration agreement with Regeneron, Alnylam will receive a $25 million payment following the approval. The company is also eligible to receive tiered, double-digit royalties of up to 15% on global net sales of the drug.
Livsayis was initially discovered by Alnylam scientists and advanced through Phase 2 clinical development before becoming part of the company’s RNAi collaboration with Regeneron.
In 2024, Regeneron assumed full responsibility for the drug’s development, manufacturing and commercialization. The company subsequently completed late-stage clinical development and secured FDA approval.
“Seven FDA-approved medicines originating from Alnylam in under nine years is powerful evidence that RNAi has become an important and differentiated platform for creating new medicines,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “Livsayis began with Alnylam science, and its approval demonstrates how our innovation can ultimately reach patients through both our own portfolio and strategic partnerships. As we look ahead, we remain focused on advancing RNAi science, expanding its application to new areas of medicine, and delivering meaningful outcomes for patients.”
Generalized myasthenia gravis is a rare, chronic autoimmune disorder that causes muscle weakness and can lead to potentially life-threatening complications.
In patients who test positive for AChR antibodies, activation of the immune system’s complement pathway contributes to damage at the neuromuscular junction, where nerve signals are transmitted to muscles.
Livsayis is designed to address this process by reducing the production of complement component 5 (C5), a protein involved in the immune response.
The treatment uses small interfering RNA (siRNA) technology to silence the messenger RNA responsible for producing the C5 protein, thereby reducing its production.
Unlike treatments requiring frequent administration, Livsayis is administered through a subcutaneous injection four times a year.
The approval represents another milestone for Alnylam’s RNAi technology platform, which uses gene-silencing mechanisms to develop treatments for a range of diseases.
For Alnylam, the regulatory decision also highlights the commercial potential of its partnerships with larger pharmaceutical companies, allowing treatments originating from its research platform to reach patients through external development and commercialization agreements.
Regeneron will be responsible for bringing Livsayis to market, while Alnylam will benefit financially through the approval payment and future royalties tied to global sales.


